Kura Oncology (KURA) Financials

Kura Oncology’s financial profile shows a company transitioning toward meaningful commercial revenue, but it remains heavily loss-making and dependent on its investment portfolio to fund operations. Revenue increased from zero in 2023 and most of 2024 to $20.9 million in Q2 2026, up from $18.3 million in Q1 2026 and $15.3 million in the restated Q2 2025 period. Gross profit was $20.6 million, representing a gross margin of approximately 99%.

Despite the revenue growth, operating expenses remain substantial. Q2 2026 research and development expense was $61.9 million, while selling, general and administrative expense was $31.8 million. Total operating expenses declined sequentially from $96.8 million to $93.6 million, helping narrow the operating loss from $78.8 million in Q1 to $73.0 million in Q2. Net loss improved to $68.3 million, compared with $73.3 million in Q1 and $81.0 million in Q4 2025, but the company has not yet reached profitability.

Cash usage remains a central investor concern. Kura used $62.5 million in operating cash flow during Q2 2026, an improvement from the $85.9 million used in Q1 but significantly worse than the $28.8 million used in Q2 2025. The company’s $31.2 million increase in cash during Q2 was primarily driven by $112.5 million of investment maturities and sales, rather than internally generated cash.

At June 30, 2026, Kura held $72.2 million in cash and $448.8 million in short-term investments, or approximately $521.0 million in highly liquid assets. This provides a substantial funding base, although continued quarterly operating losses could reduce that cushion. Total liabilities were $539.4 million, including $454.1 million of deferred revenue, while total debt was relatively modest at approximately $9.8 million.

• Revenue is trending upward: Quarterly revenue rose from $14.1 million in Q1 2025 to $20.9 million in Q2 2026, indicating expanding commercial activity.
• Very high gross margins: Q2 2026 gross margin was approximately 99%, suggesting that incremental revenue could provide meaningful operating leverage if growth continues.
• Large liquidity position: Cash and short-term investments totaled approximately $521.0 million at the end of Q2 2026, giving Kura significant financial resources relative to its quarterly operating cash burn.
• Sequential improvement in losses and cash burn: Net loss improved from $81.0 million in Q4 2025 to $68.3 million in Q2 2026, while operating cash outflow improved from $85.9 million in Q1 to $62.5 million in Q2.
• Limited debt burden: Short- and long-term debt totaled approximately $9.8 million, reducing interest-rate and refinancing risk compared with a highly leveraged balance sheet.
• Deferred revenue provides potential future revenue recognition: Current and noncurrent deferred revenue totaled approximately $454.1 million in Q2 2026, up from about $320.5 million in Q2 2025. This may support future reported revenue, although the timing and profitability of recognition remain important.
• Investment activity is driving cash fluctuations: Kura frequently purchases and sells short-term investments. Consequently, quarterly changes in cash may reflect portfolio management rather than operating performance.
• Recent financial statements include restatements: Several 2024 and 2025 income statement and cash flow periods were restated, so investors should exercise caution when comparing historical figures across filings.
• Operating cash flow remains deeply negative: Kura used $62.5 million in operating cash during Q2 2026, meaning its revenue base is not yet sufficient to fund research, development, and corporate expenses.
• Persistent losses and rising accumulated deficits: Kura reported a $68.3 million Q2 net loss, and retained earnings declined to negative $1.32 billion, highlighting the company’s long history of losses and continued need to reach profitability.